To evaluate the treatment outcomes of high-dose-rate brachytherapy (HDR-BT) in prostate cancer patients aged 75 and older, specifically comparing these outcomes to those of younger patients.
Key Findings:
Higher doses of radiation correlate with improved outcomes in prostate cancer treatment.
Combining HDR-BT with EBRT enhances disease-free survival compared to EBRT alone.
Limited high-quality evidence exists regarding HDR-BT outcomes specifically for older patients, highlighting a critical gap in research.
Interpretation:
The study highlights the effectiveness of HDR-BT in older prostate cancer patients, suggesting it is a viable treatment option despite their increased comorbidities, which may complicate treatment decisions.
Limitations:
The study is retrospective and may have inherent biases that could affect the reliability of the findings.
Limited generalizability due to the specific patient population and treatment protocols used, which may not reflect broader clinical practices.
Conclusion:
HDR-BT is a promising treatment for prostate cancer in patients aged 75 and older, warranting further research to establish comprehensive outcomes.
